Altimmune, Inc. (ALT)
ALT Stock Price Chart
Explore Altimmune, Inc. interactive price chart. Choose custom timeframes to analyze ALT price movements and trends.
ALT Company Profile
Discover essential business fundamentals and corporate details for Altimmune, Inc. (ALT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 May 2017
Employees
59.00
Website
https://altimmune.comCEO
Vipin K. Garg
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Financial Timeline
Browse a chronological timeline of Altimmune, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.30, while revenue estimate is $560.00.
Earnings released on 12 Aug 2025
EPS came in at -$0.27 surpassing the estimated -$0.32 by +15.62%, while revenue for the quarter reached $5.00K , beating expectations by +249.90%.
Earnings released on 13 May 2025
EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.71%, while revenue for the quarter reached $5.00K , beating expectations by +792.86%.
Earnings released on 27 Feb 2025
EPS came in at -$0.33 surpassing the estimated -$0.34 by +2.94%, while revenue for the quarter reached $5.00K , beating expectations by +400.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%, while revenue for the quarter reached $5.00K , beating expectations by +600.28%.
Earnings released on 8 Aug 2024
EPS came in at -$0.35 falling short of the estimated -$0.34 by -2.94%, while revenue for the quarter reached $5.00K , beating expectations by +600.28%.
Earnings released on 9 May 2024
EPS came in at -$0.34 surpassing the estimated -$0.36 by +5.56%, while revenue for the quarter reached $5.00K .
Earnings released on 27 Mar 2024
EPS came in at -$0.33 surpassing the estimated -$0.35 by +5.71%, while revenue for the quarter reached $37.00K , beating expectations by +1.63K%.
Earnings released on 7 Nov 2023
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $362.00K , beating expectations by +42.14K%.
Earnings released on 10 Aug 2023
EPS came in at -$0.32 surpassing the estimated -$0.44 by +27.27%, while revenue for the quarter reached $6.00K , beating expectations by +100.00%.
Earnings released on 11 May 2023
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $21.00K .
Earnings released on 28 Feb 2023
EPS came in at -$0.43 surpassing the estimated -$0.52 by +17.31%, while revenue for the quarter reached -$110.00K , missing expectations by -481.19%.
Earnings released on 10 Nov 2022
EPS came in at -$0.48 surpassing the estimated -$0.49 by +2.04%, while revenue for the quarter reached $2.00K , missing expectations by -99.77%.
Earnings released on 11 Aug 2022
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $8.00K , missing expectations by -99.08%.
Earnings released on 12 May 2022
EPS came in at -$0.44 surpassing the estimated -$0.57 by +22.81%, while revenue for the quarter reached $32.00K , missing expectations by -96.90%.
Earnings released on 15 Mar 2022
EPS came in at -$0.49 surpassing the estimated -$0.64 by +23.44%, while revenue for the quarter reached $3.28M , beating expectations by +3.53K%.
Earnings released on 9 Nov 2021
EPS came in at -$0.81 falling short of the estimated -$0.36 by -125.00%, while revenue for the quarter reached $157.56K , beating expectations by +7.75%.
Earnings released on 10 Aug 2021
EPS came in at -$0.40 surpassing the estimated -$0.44 by +9.09%, while revenue for the quarter reached $137.62K , missing expectations by -92.72%.
Earnings released on 17 May 2021
EPS came in at -$0.38 surpassing the estimated -$0.39 by +2.56%, while revenue for the quarter reached $837.52K , missing expectations by -60.12%.
Earnings released on 25 Feb 2021
EPS came in at -$0.17 surpassing the estimated -$0.84 by +79.76%, while revenue for the quarter reached $2.31M , missing expectations by -37.34%.
Earnings released on 9 Nov 2020
EPS came in at -$0.54 surpassing the estimated -$0.92 by +41.30%, while revenue for the quarter reached $2.94M , missing expectations by -22.45%.
ALT Stock Performance
Access detailed ALT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.